![]() | |
| 公司名 | BOC Sciences |
| 联系人 | Linna Green |
| 电 话 | +16314854226 |
| 手 机 | +16314854226 |
| 电子邮件 | info@bocsci.com |
| 网 址 | http://www.bocsci.com/ |
| 地 区 | 其他 |
| 邮 编 | 11967 |
在线询盘仅适合非紧急采购的情形,您需要留下收货地域,采购数量及联系方式。供应商在收到您的询盘信息后,会通过您留下的联系方式联络您。如果您希望立即和供应商交谈,请直接拨打供应商电话。供应商手机:+16314854226
| 中文名 | 拉索昔芬 |
| 英文名 | Lasofoxifene |
| 别名 | 拉索昔芬;拉索昔芬-D4;(5R,6S)-5,6,7,8-四氢-6-苯基-5-(4-(2-(1-吡咯烷基)乙氧基)苯基)-2-萘酚 |
| CAS | 180916-16-9 |
| EINECS | |
| 化学式 | C28H31NO2 |
| 分子量 | 413.55 |
| inchi | |
| 包装信息 | 100 mg |
| 价格 | $838 |
| 产品描述 | 拉索昔芬 Lasofoxifene (INN) (proposed tradename Fablyn) is a non-steroidal selective estrogen receptor modulator (SERM) which is under development by Pfizer for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy, and the result of an exclusive research collaboration with Ligand Pharmaceuticals (LGND). In September 2005, Pfizer received a non-approvable letter from the U.S. Food and Drug Administration regarding lasofoxifene ( Oporia), a selective estrogen receptor modulator for the prevention of osteoporosis. Lasofoxifene was approved in the EU under the Fablyn by the EMEA in March 2009. Lasofoxifene is a desmethyl dihydro analog of nafoxidine. |
| 产品链接 | http://www.bocsci.com/product/lasofoxifene-cas-180916-16-9-465309.html |
| 更新日期 | 2025-04-30 11:27:47 |